Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell, Peripheral 13Lymphoma, T-Cell, Cutaneous 13Lymphoma, T-Cell 12Lymphoma, Large-Cell, Anaplastic 8Lymphoma 7Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Mycosis Fungoides 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Burkitt Lymphoma 3Breast Neoplasms 3Sezary Syndrome 2Lymphoma, Extranodal NK-T-Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × romidepsin × Clear all
NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

University of Kansas Medical Center

Phase 1/2 Active not recruiting
51 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡